Schrödinger's 12% ACV Growth Isn't Fully Priced-But Investors Still Fear the AI Hype Tax

Q1 results show demand holding even as margins wobble

Schrödinger's latest quarter gives investors two different stories at once. ACV grew 12%, Q1 revenue of $58.6 million beat estimates by 21.78%, and management said the biopharmaceutical funding environment is improving. At the same time, the income statement still looks messy: software gross margin compressed and EPS missed expectations. That is why the stock feels caught between a real operating transition and an AI skepticism discount.

The market is focusing on the near-term hit to profitability, which is understandable. But the more constructive signal is customer behavior. Management said ACV growth was driven by usage scale-ups and new deployments, which suggests customers are deepening use of the platform even while Schrödinger moves toward hosted licensing. That is the behavior investors want to see before the P&L fully normalizes.

Proof of impact is also becoming easier to point to. Lilly's $2.3 billion acquisition of Ajax Therapeutics reinforces that Schrödinger's platform has helped produce assets with serious commercial value. And in a market where AI credibility matters, Schrödinger still fits the profile of a company where the technology is central to adoption and monetization: in 2026, 43 of the 50 companies say AI is essential.

Drug discovery revenue is becoming the more important signal

The mix shift in Q1 matters. Drug discovery revenue surged 124% year over year to $22.9 million, while software revenue declined 21%. That does not prove the hosted model is already working cleanly, but it does suggest customers still see Schrödinger as valuable for actual discovery work, not just as a software license.

That distinction is important. Software revenue can look uneven during a business-model transition, but discovery revenue is harder to dismiss because it sits closer to clinical pipeline value and customer switching costs. Once Schrödinger's models are helping prioritize molecules and shape discovery campaigns, the relationship becomes more embedded in the customer workflow.

Product depth is increasing, not just the pitch

Management also said Schrödinger plans to launch Bunsen, an agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows and broaden platform utilization. If that lands, it could make the platform stickier by owning more of the workflow rather than only assisting individual tasks.

The integration of Lilly TuneLab into LiveDesign points in the same direction. Combined workflows and enterprise informatics tie the platform more directly into how customers organize discovery work, which is a stronger position than being merely adjacent to it.

The debate now is timing, not whether the platform matters

The bull case is straightforward: the platform appears to be getting deeper into customer workflows, and therapeutic proof points are becoming harder to ignore.

The bear case is narrower, but still real: - drug discovery is still a relatively small revenue segment - software revenue remains under pressure - margin recovery is expected only as the hosted transition completes by 2028

The core setup is that Schrödinger no longer looks like a pure AI narrative. The remaining question is whether the company can get through the transition well enough for the market to reward the contract growth and workflow entrenchment it is already showing.

What would close the valuation gap